Q4 Earnings Estimate for Vericel Issued By Leerink Partnrs

Vericel Co. (NASDAQ:VCEL) – Equities research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share estimates for Vericel in a research report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the biotechnology company will post earnings per share of $0.32 for the quarter, down from their prior estimate of $0.33. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. Leerink Partnrs also issued estimates for Vericel’s Q4 2025 earnings at $0.36 EPS, FY2025 earnings at $0.38 EPS, FY2026 earnings at $0.80 EPS, FY2027 earnings at $1.34 EPS and FY2028 earnings at $1.79 EPS.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. The firm had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%.

Several other equities research analysts have also issued reports on the stock. TD Cowen raised their price target on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Vericel in a research report on Friday, November 8th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Tuesday, November 19th. Stephens lifted their price objective on Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Canaccord Genuity Group assumed coverage on shares of Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $58.14.

Vericel Stock Performance

NASDAQ VCEL opened at $58.62 on Tuesday. The company has a market capitalization of $2.89 billion, a PE ratio of 977.00 and a beta of 1.66. Vericel has a 52-week low of $32.31 and a 52-week high of $61.49. The company has a 50-day simple moving average of $46.41 and a 200 day simple moving average of $47.07.

Institutional Trading of Vericel

A number of large investors have recently modified their holdings of VCEL. Silvercrest Asset Management Group LLC bought a new stake in Vericel during the first quarter valued at approximately $6,538,000. Scholtz & Company LLC purchased a new position in Vericel in the second quarter worth $1,357,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Vericel by 4.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company’s stock valued at $45,590,000 after acquiring an additional 47,108 shares during the last quarter. Premier Fund Managers Ltd purchased a new stake in Vericel during the third quarter valued at about $781,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Vericel by 6.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 420,643 shares of the biotechnology company’s stock worth $19,299,000 after purchasing an additional 25,626 shares during the last quarter.

Insider Activity

In related news, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the sale, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,595,700. This trade represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the transaction, the chief executive officer now owns 220,937 shares in the company, valued at $9,142,373.06. This represents a 7.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 31,666 shares of company stock worth $1,350,764 over the last ninety days. Company insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.